• 4982 Citations
  • 29 Scopus h-Index
20022019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Minetta C Liu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
Triple Negative Breast Neoplasms Medicine & Life Sciences
Circulating Neoplastic Cells Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Biomarkers Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2019

  • 4982 Citations
  • 29 Scopus h-Index
  • 62 Article
  • 3 Review article
  • 2 Chapter
  • 1 Letter

Available and emerging molecular markers in the clinical management of breast cancer

Giridhar, K. V. & Liu, M. C., Oct 3 2019, In : Expert Review of Molecular Diagnostics. 19, 10, p. 919-928 10 p.

Research output: Contribution to journalReview article

Biomarkers
Breast Neoplasms
Microsatellite Instability
Mutation
Neoadjuvant Therapy

Circulating Tumor DNA and Hepatocellular Carcinoma

Yang, J. D., Liu, M. C. & Kisiel, J. B., Jan 1 2019, In : Seminars in Liver Disease. 39, 4, p. 452-462 11 p.

Research output: Contribution to journalArticle

Hepatocellular Carcinoma
DNA
Neoplasms
Methylation
Technology

Integration of Comprehensive Genomic Analysis and Functional Screening of Affected Molecular Pathways to Inform Cancer Therapy

Vasmatzis, G., Liu, M. C., Reganti, S., Feathers, R. W., Smadbeck, J., Johnson, S. H., Schaefer Klein, J. L., Harris, F. R., Yang, L., Kosari, F., Murphy, S. J., Borad, M. J., Thompson, E. A., Cheville, J. C. & Anastasiadis, P. Z., Jan 1 2019, (Accepted/In press) In : Mayo Clinic proceedings.

Research output: Contribution to journalArticle

Open Access
Neoplasms
Mutation
Therapeutics
Precision Medicine
Preclinical Drug Evaluations

Oncolytic Measles Virotherapy and Opposition to Measles Vaccination

Russell, S. J., Babovic-Vuksanovic, D., Bexon, A., Cattaneo, R., Dingli, D., Dispenzieri, A., Deyle, D. R., Federspiel, M. J., Fielding, A., Galanis, E., Lacy, M. Q., Leibovich, B. C., Liu, M. C., Muñoz-Alía, M., Miest, T. C., Molina, J. R., Mueller, S., Okuno, S. H., Packiriswamy, N., Peikert, T. & 6 others, Raffel, C., Van Rhee, F., Ungerechts, G., Young, P. R., Zhou, Y. & Peng, K. W., Jan 1 2019, In : Mayo Clinic proceedings.

Research output: Contribution to journalReview article

Open Access
Oncolytic Virotherapy
Measles
Vaccination
Measles virus
Immunity
30 Citations (Scopus)

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study

Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., De Laurentiis, M., Nanda, R., Winer, E. P., Mukai, H., Tamura, K., Armstrong, A., Liu, M. C., Iwata, H., Ryvo, L., Wimberger, P., Rugo, H. S., Tan, A. R., Jia, L., Ding, Y., Karantza, V. & Schmid, P., Mar 1 2019, In : Annals of Oncology. 30, 3, p. 405-411 7 p.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
Therapeutics
Disease-Free Survival
pembrolizumab
Safety